*****Clearly, Squalamine’s advantage in convenience and safety relative to the intravitreally administered drugs (Macugen and Lucentis) becomes even larger when one considers the amount of retreatment required to reach the point of ultimate success or failure in arresting disease with a given patient. So the retreatment issue is likely to be a key selling point for Squalamine relative to Macugen and Lucentis.****
Dew, many thanks for your detailed reply. This is the kind of discussion that should be taking place on Yahoo, but the noise over there is too distracting. I now understand the difference between the initial treatment (a series of 4 weekly treatments) and the retreatment (1 month, 6 weeks, or 3 months). I lost you somewhere in the paragraph I quoted above. Am I correct in thinking that the retreatment schedule of squalamine is now 3 months, and the Phase II trial in question would test whether there is any advantage to a monthly retreatment schedule?
Market Data 
Markets 
AI
